The James P. Wilmot Cancer Center has been named as one of the Top 70 Oncology programs in the United States by Becker’s Hospital Review, one of the nation’s foremost publications on up-to-date business and legal news and analysis relating to hospitals and health systems. With its inclusion on the Top 70 list, the Wilmot Cancer Center joins the ranks of some of the country’s most notable cancer centers, including Cleveland Clinic, Dana-Farber, Duke University, Johns Hopkins, the Mayo Clinic and the University of Texas’ M.D. Anderson Cancer Center.
Becker's Hospital Review editorial team formed the Top 70 list based on clinical accolades, quality care and contributions to the field of oncology. Their analysis utilized data from reputable healthcare rating resources, including U.S. News & World Report, HealthGrades, Thomson Reuters, the National Cancer Institute, the American College of Surgeons and the American Nurses Credentialing Center.
The Wilmot Cancer Center and the others on the list were characterized as having demonstrated continual innovation in treatments and services, patient-centered care, and the achievement of clinical milestones and groundbreaking discoveries. The Becker’s editors specifically cited that radiation oncology experts at the Wilmot Cancer Center were the first to successfully take a new brain cancer treatment — shaped-beam radiosurgery — and apply it to patients suffering from cancer that spread to the lungs and other organs. They also noted that University of Rochester Medical Center and Wilmot scientists also discovered a method to protect against HPV strains, which led to the first anti-cancer and HPV vaccine approved by the FDA in 2006.
“This is a wonderful affirmation of our ongoing mission to bring the very best in cancer care and research to the greater Rochester community and well beyond,” said Richard I. Fisher, M.D., director of the Wilmot Cancer Center. “This type of recognition does not happen by chance. It is the result of drawing some of the nation’s best and brightest clinicians and scientists to Rochester, as well as our firm commitment to multidisciplinary, specialized cancer care – the model used by the leading cancer programs in the world. I applaud the efforts of our entire team of physicians, scientists and staff and am confident that our continued focus on research and a highly collaborative strategic planning process will continue to bring ever-improving, leading-edge care to those battling cancer.”